metformin has been researched along with osteoprotegerin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, CW; Cha, BS; Cho, MH; Kim, KR; Lee, HC; Nam, JS; Park, JS; Yoo, JS | 1 |
| Bai, XC; Jia, CH; Jin, DD; Lu, M; Mai, QG; Wen, ZH; Xu, S; Zhang, ZM; Zhao, L; Zhou, RP | 1 |
| Hu, Y; Liu, L; Peng, B; Zhang, C | 1 |
| Feng, Y; Liu, HC; Liu, JQ | 1 |
| Chen, TY; Duan, Y; Qin, S; Wang, G; Wang, J | 1 |
| Cao, X; Shao, X; Shi, B; Song, G; Zhao, Y | 1 |
| Afarideh, M; Azizi, R; Ebadi, M; Esteghamati, A; Mousavizadeh, M; Nakhjavani, M; Noshad, S | 1 |
| Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ | 1 |
| Shargorodsky, M; Sofer, E | 1 |
| Arslan, MS; Biyikli Gencturk, Z; Cakal, E; Delibasi, T; Karakose, M; Ozbek, M; Ozturk, G; Sahin, M; Tutal, E; Ucan, B | 1 |
| Cao, X; Lu, Z; Tian, X; Wei, D; Yan, Z; Ye, Z; Zhai, D; Zhu, Q; Zhu, S; Zhu, Z | 1 |
| Jasmine, MR; Nanda, N; Pal, GK; Sahoo, J; Velkumary, S | 1 |
3 trial(s) available for metformin and osteoprotegerin
| Article | Year |
|---|---|
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Thiazolidinediones | 2011 |
The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Sex Characteristics; Thiazolidinediones | 2015 |
Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alkaline Phosphatase; Double-Blind Method; Down-Regulation; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Osteoprotegerin; Treatment Outcome | 2016 |
9 other study(ies) available for metformin and osteoprotegerin
| Article | Year |
|---|---|
Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
Topics: Animals; Blotting, Western; Cell Differentiation; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Metformin; Mice; Osteoblasts; Osteoporosis; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Skull; Tibia | 2011 |
Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Bone Remodeling; Injections, Intramuscular; Male; Metformin; Osteoclasts; Osteoprotegerin; Periapical Periodontitis; RANK Ligand; Rats; Rats, Wistar | 2012 |
AMP-activated protein kinase acts as a negative regulator of high glucose-induced RANKL expression in human periodontal ligament cells.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Cells, Cultured; Glucose; Humans; Metformin; Osteoprotegerin; Periodontal Ligament; RANK Ligand; Real-Time Polymerase Chain Reaction | 2012 |
Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Topics: Bone Neoplasms; Diabetes Complications; Gene Expression Regulation, Neoplastic; Humans; Metformin; Models, Biological; Osteoclasts; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B | 2013 |
Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation.
Topics: Alkaline Phosphatase; Biomarkers; Cell Line; Cell Proliferation; Collagen Type I; Collagen Type I, alpha 1 Chain; Enzyme Repression; Gene Expression Regulation; Humans; Hyperglycemia; Hypoglycemic Agents; Kinetics; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metformin; Osteoblasts; Osteocalcin; Osteogenesis; Osteoprotegerin; Protective Agents; Up-Regulation | 2014 |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Coronary Vessels; Diabetes Mellitus, Type 2; Endpoint Determination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Muscle, Smooth, Vascular; Osteoprotegerin; Pilot Projects; Prospective Studies; Sialoglycoproteins; Vascular Calcification | 2015 |
Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Life Style; Male; Metformin; Middle Aged; Osteoprotegerin; Prediabetic State; RANK Ligand; Treatment Outcome; Waist Circumference | 2017 |
Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Bone and Bones; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Glycoproteins; Inflammation; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice, Inbred C57BL; Models, Biological; Organ Size; Osteocytes; Osteogenesis; Osteolysis; Osteoprotegerin; Phosphorylation; Polyethylenes; Protective Agents; RANK Ligand; Skull | 2019 |
Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs.
Topics: Administration, Oral; Adult; Biomarkers; Cardiometabolic Risk Factors; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heart; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Osteoprotegerin; Risk Assessment; Sulfonylurea Compounds; Treatment Outcome; Up-Regulation; Vagus Nerve | 2020 |